Wednesday, April 26, 2023
ALX Oncology Holdings announced that it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate evorpacept in combination with SARCLISA (isatuximab-irfc) in patients with multiple myeloma.
This collaboration with Sanofi has the potential to advance a new combination therapy for patients with relapsed multiple myeloma who will benefit from novel effective treatment options. Moreover, collaboration expands robust clinical development pipeline with evorpacept, to establish a new and best-in-class foundational immunotherapy in both haematologic and solid tumours.
Under the terms of the agreement, Sanofi will conduct a Phase 1/2 study to evaluate the safety, efficacy, pharmacokinetics and biomarker data of evorpacept in combination with SARCLISA and dexamethasone in patients with RRMM.
Part 1 will evaluate dosing of evorpacept in combination with standard doses of SARCLISA and dexamethasone to identify a recommended dose. Part 2 will investigate the efficacy and safety of this combination in an expanded population of patients with RRMM. ALX Oncology will supply evorpacept and Sanofi will supply SARCLISA for this study.
